(Q33863201)

29 July 2017

1 reference

title

HLA class I expression on human cancer cells. Implications for effective immunotherapy (English)

1 reference

29 July 2017

1 reference

Tait BD

1

1 reference

29 July 2017

publication date

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

volume

61

1 reference

29 July 2017

issue

2

1 reference

29 July 2017

page(s)

158-165

1 reference

Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system.

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Structure of the human class I histocompatibility antigen, HLA-A2

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Immunological determinants of polyoma virus oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Effect of leukocytes on transplantability of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Demonstration of cell-bound and humoral immunity against neuroblastoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Cellular and Humoral immunity to Different Types of Human Neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA-Cw*1601.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Cellular mucins: targets for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Active immunization of metastatic melanoma patients with interleukin-4 transduced, allogeneic melanoma cells. A phase I-II study

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A phase I trial of human gamma interferon transduced autologous tumor cells in patients with disseminated malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Phase I evaluation of interleukin-2-transfected irradiated allogeneic melanoma for the treatment of metastatic melanoma: appendix 1: protocol

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Immunotherapy of cancer with dendritic-cell-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Transloading of tumor antigen-derived peptides into antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Breast cancer immunotherapy: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Clinical Activity of a Polyvalent Melanoma Antigen Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Direct gene transfer for treatment of human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

The new vaccines: building viruses that elicit antitumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

DNA immunization targeting the skin: molecular control of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Recombinant Listeria monocytogenes cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Gene-based strategies for the immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

High frequency of altered HLA class I phenotypes in invasive breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Can the HLA phenotype be used as a prognostic factor in breast carcinomas?

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Selective changes in expression of HLA class I polymorphic determinants in human solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Altered HLA expression by metastatic cervical carcinoma cells as a factor in impaired immune surveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Proto-oncogene PML controls genes devoted to MHC class I antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Comparison of natural killer (NK) sensitivities of two tumor cell lines established from a cancer patient before and after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Expression of MHC class I and class II antigens in pancreatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Heat shock protein 70 and HLA-DR molecules tissue expression. Prognostic implications in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

Immunohistochemically demonstrated expression of HLA‐DR antigen in colorectal adenocarcinomas and its relation to clinicopathological features

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

A comparison of flow cytometry and immunohistochemistry in human colorectal cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2899%2900150-0

7 January 2021

10.1016/S0198-8859(99)00150-0

Identifiers

DOI

1 reference

29 July 2017

1 reference